Piper Jaffray analyst Danielle Brill kept her Overweight rating and $38 price target on MorphoSys following her meeting with its CEO Simon Maroney at Piper Jaffray Healthcare Conference. The analyst notes that the company remains focused on the development of MOR208 and believes that the drug could become “cornerstone” of Diffuse Large B-Cell Lymphoma, or DBLCL, therapy, remaining “very bullish” on the name. Brill adds that her survey of doctors treating lymphoma at the conference revealed that 46% would use MOR208 for their DBLCL patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.